Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: The EVERE2ST-HIV study

European Heart Journal

Volumn 38, Issue 21, 2017, Pages 1676-1686

  Hauguel Moreau, Marie ^a   Boccara, Franck ^a,b   Boyd, Anders ^a   Salem, Joe Elie ^a   Brugier, Delphine ^a   Curjol, Angélique ^a   Hulot, Jean Sébastien ^a   Kerneis, Mathieu ^a   Galier, Sophie ^a   Cohen, Ariel ^a   Montalescot, Gilles ^a   Collet, Jean Philippe ^a   Silvain, Johanne ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

Author keywords

Acute coronary syndromes; Antiretroviral therapy; Dual antiplatelet therapy; Human immunodeficiency virus; Platelet reactivity

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ATAZANAVIR; CLOPIDOGREL; DARUNAVIR; INDINAVIR; LOPINAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASUGREL; PURINERGIC P2Y RECEPTOR; RITONAVIR; TICAGRELOR; ADENOSINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG RESPONSE; DUAL ANTIPLATELET THERAPY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLATELET REACTIVITY; PREVALENCE; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK FACTOR; THROMBOCYTE;

ACUTE CORONARY SYNDROME; ADENOSINE; ANTI-HIV AGENTS; ASPIRIN; BLOOD PLATELETS; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECURRENCE; RISK FACTORS; TICLOPIDINE;

EID: 85020888323     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw583     Document Type: Article

References (31)

1. Boccara F, Lang S, Meuleman C, Ederhy S, Mary-Krause M, Costagliola D, Capeau J, Cohen A. HIV and coronary heart disease: Time for a better understanding. J Am Coll Cardiol 2013;61:511-523.
2. Zanni MV, Abbara S, Lo J, Wai B, Hark D, Marmarelis E, Grinspoon SK. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. Aids 2013;27:1263-1272.
3. El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fatkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C. Strategies for Management of Antiretroviral Therapy Study GroupCD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
4. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Darminio Monforte A, Friis-Moller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. D:A:D Study GroupUse of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration. Lancet 2008;371:1417-1426.
5. Satchell CS, Ohalloran JA, Cotter AG, Peace AJ, Oconnor EF, Tedesco AF, Feeney ER, Lambert JS, Sheehan GJ, Kenny D, Mallon PW. Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy. J Infect Dis 2011;204:1202-1210.
6. Falcinelli E, Francisci D, Belfiori B, Petito E, Guglielmini G, Malincarne L, Mezzasoma A, Sebastiano M, Conti V, Giannini S, Bonora S, Baldelli F, Gresele P. In vivo platelet activation and platelet hyperreactivity in abacavir-Treated HIV-infected patients. Thromb Haemost 2013;110:349-357.
7. Boccara F, Mary-Krause M, Teiger E, Lang S, Lim P, Wahbi K, Beygui F, Milleron O, Gabriel Steg P, Funck-Brentano C, Slama M, Girard PM, Costagliola D, Cohen A. Prognosis of Acute Coronary Syndrome in HIV-infected patients (PACS) Investigators. Acute coronary syndrome in human immunodeficiency virusinfected patients: characteristics and 1 year prognosis. Eur Heart J 2011;32:41-50.
8. Boccara F, Miantezila Basilua J, Mary-Krause M, Lang S, Teiger E, Steg PG, Funck-Brentano C, Costagliola D, Cohen A, Guiguet M. Lipid profile after acute coronary syndrome in HIV-infected individuals. Results from the PACS-HIV case-control study. Eur Heart J 2014;35:494(Abstract P2708).
9. DAscenzo F, Cerrato E, Biondi-Zoccai G, Moretti C, Omede P, Sciuto F, Bollati M, Modena MG, Gaita F, Sheiban I. Acute coronary syndromes in human immunodeficiency virus patients: A meta-Analysis investigating adverse event rates and the role of antiretroviral therapy. Eur Heart J 2012;33:875-880.
10. Brar SS, ten Berg J, Marcucci R, Price MJ, Valgimigli M, Kim HS, Patti G, Breet NJ, DiSciascio G, Cuisset T, Dangas G. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-Analysis of individual participant data. J Am Coll Cardiol 2011;58:1945-1954.
11. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-Term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 2011;306:1215-1223.
12. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009;373:309-317.
13. Cayla G, Hulot JS, Oconnor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignalou JB, Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthelemy O, Montalescot G, Collet JP. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 2011;306:1765-1774.
14. Silvain J, Cayla G, Hulot JS, Finzi J, Kerneis M, Oconnor SA, Bellemain-Appaix A, Barthelemy O, Beygui F, Collet JP, Montalescot G. High on-Thienopyridine platelet reactivity in elderly coronary patients: The SENIOR-PLATELET study. Eur Heart J 2012;33:1241-1249.
15. Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009;119:2625-2632.
16. Abtan J, Silvain J, Kerneis M, Oconnor SA, Barthelemy O, Vignalou JB, Beygui F, Brugier D, Collet JP, Montalescot G. Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-Associated stimulated phosphoprotein (VASP) phosphorylation assay. Thromb Haemost 2013;110:1055-1064.
17. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA. Working Group on On-Treatment Platelet Reactivity Consensus and update on the definition of on-Treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62:2261-2273.
18. Angiolillo DJ, Jakubowski JA, Ferreiro JL, Tello-Montoliu A, Rollini F, Franchi F, Ueno M, Darlington A, Desai B, Moser BA, Sugidachi A, Guzman LA, Bass TA. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. J Am Coll Cardiol 2014;64:1005-1014.
19. Zucker-Franklin D, Seremetis S, Zheng ZY. Internalization of human immunodeficiency virus type I and other retroviruses by megakaryocytes and platelets. Blood 1990;75:1920-1923.
20. Youssefian T, Drouin A, Masse JM, Guichard J, Cramer EM. Host defense role of platelets: engulfment of HIV and Staphylococcus aureus occurs in a specific subcellular compartment and is enhanced by platelet activation. Blood 2002;99:4021-4029.
21. Corrales-Medina VF, Simkins J, Chirinos JA, Serpa JA, Horstman LL, Jy W, Ahn YS. Increased levels of platelet microparticles in HIV-infected patients with good response to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2010;54:217-218.
22. Funderburg NT, Lederman MM. Coagulation and morbidity in treated HIV infection. Thromb Res 2014;133(Suppl 1):S21-S24.
23. OBrien M, Montenont E, Hu L, Nardi MA, Valdes V, Merolla M, Gettenberg G, Cavanagh K, Aberg JA, Bhardwaj N, Berger JS. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: A pilot study. J Acquir Immune Defic Syndr 2013;63:280-288.
24. Nkambule BB, Davison GM, Ipp H. The evaluation of platelet function in HIV infected, asymptomatic treatment-naive individuals using flow cytometry. Thromb Res 2015;135:1131-1139.
25. Rezer JF, Souza VC, Thorstenberg ML, Ruchel JB, Bertoldo TM, Zanini D, Silveira KL, Leal CA, Passos DF, Goncalves JF, Abdalla FH, Schetinger MR, Leal DB. Effect of antiretroviral therapy in thromboregulation through the hydrolysis of adenine nucleotides in platelets of HIV patients. Biomed Pharmacother 2016;79:321-328.
26. Egan GHC, Tseng A, Ackman ML, Alberta Health Services. Interactions Between Antiretrovirals and Antiplatelet Agents and Novel Oral Anticoagulants. University Health Network-Toronto General Hospital. http://hivclinic.ca/druginformation/drug-interaction-Tables/(December 2014 Updated May 2015).
27. Gili S, Grosso Marra W, DAscenzo F, Lonni E, Calcagno A, Cannillo M, Ballocca F, Cerrato E, Pianelli M, Barbero U, Mancone M, DiNicolantonio JJ, Lavie CJ, Omed OP, Montefusco A, Bonora S, Gasparini M, Biondi-Zoccai G, Moretti C, Gaita F. Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: A systematic review and metaanalysis. Eur Heart J 2016;37:3600-3609.
28. Xu C, Desta Z. In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug Metab Pharmacokinet 2013;28:362-371.
29. Saez CG, Pereira-Flores K, Ebensperger R, Panes O, Massardo T, Hidalgo P, Mezzano D, Pereira J. Atorvastatin reduces the proadhesive and prothrombotic endothelial cell phenotype induced by cocaine and plasma from cocaine consumers in vitro. Arterioscler Thromb Vasc Biol 2014;34:2439-2448.
30. Cagienard F, Schulzki T, Reinhart WH. Cocaine in high concentrations inhibits platelet aggregation in vitro. Clin Hemorheol Microcirc 2014;57:385-394.
31. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrie D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monsegu J, Sabouret P, Oconnor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthelemy O, Beygui F, Silvain J, Vicaut E, Montalescot G. ARCTIC Investigators Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012;367:2100-2109.